Bright Minds Biosciences Inc.

DRUG | NASDAQ

Price Alert Chart Builder DCF Calculator

$62.37

+$2.91 (+4.89%)

Sep 22, 2026, 11:46 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.89%

(1D)

Rating

Updated: Sep 1, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $610.42M

1D Range

60.15 62.39

52W Range

48.90 123.75

Valuation (TTM)

PE -29.76

PB 2.68

EV/EBITDA -15.26

Valuation (NTM)

Forward PE N/A

Forward PEG -0.20

Price Target $182.50

Cash Flow

FCF Yield -3.1%

SBC Adj. FCF Yield -3.4%

SBC Impact -9.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -52.6% | 28.8%

FCF 3Y | 5Y -94.8% | -19.4%

Returns

ROA -8.0%

ROE -12.6%

ROIC -12.9%

Financial Health

Net Cash

C$308.27M ($217.17M)

Current Ratio 121.97

Interest Coverage -2,336.36

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2...

Sector Healthcare

Industry Biotechnology

Employees 26

IPO Date Mar 21, 2021

Website www.brightmindsbio.com

Fiscal Year October - September

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$182.50

Upside

+192.61%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞